Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warnings
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Based on evidence of an increased risk of death, drug agencies issued safety warnings about the use of second generation antipsychotics (SGAs) in the elderly with dementia in 2004. This warning was extended to all antipsychotics in 2008. Little is known about the impact of these warnings on use. We conducted a quasi-experimental study (interrupted time-series) in France, for 2003–2011, including subjects aged ≥65 with dementia and subjects aged ≥65 without dementia in the EGB database (1/97th representative random sample of claims from the main Health Insurance scheme). Outcomes were monthly rates of use of antipsychotics (by class and agent) and of 5 comparison drug classes (antidepressants, benzodiazepines, dermatologicals, antidiabetics, antiasthmatics). Trends were analyzed by joinpoint regression, impact of warnings by linear segmented regression. In patients with dementia (n=7169), there was a 40% reduction in antipsychotic use from 14.2% in 2003 to 10.2% in 2011. The reduction began before 2004 and was unaffected by the warnings. Use of first generation antipsychotics declined over the period, while use of SGAs increased and leveled off from 2007. Use of the 5 comparison drug classes increased on the period. In subjects without dementia (n=91942), rates of overall antipsychotic use decreased from 2.3% in 2003 to 1.8% in 2011 with no effect of the warnings. Meanwhile, use of SGAs continuously increased from 0.37% to 0.64%. Antipsychotic use decreased in the elderly between 2003 and 2011, especially in dementia. The timing of the decrease, however, did not coincide with safety warnings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Segmented regression analysis of interrupted time series studies in medication use research
Wagner, A. K., Soumerai, S. B., Zhang, F., & Ross-Degnan, D. (2002) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2002.00430.x · Cited by 3,279 · cited 3×
“Therefore, we conducted segmented regression analyses (Wagner et al., 2002) on 3 segments based on the time of the 2 main warnings: 1- pre-SGA warning segment (January 1 2003 – February 29 2004), 2- post-SGA warning and pre-FGA warning segment (April 1 2004 – November 31 2008) and 3- post-warning for all antipsychotic…”
BackgroundMethodInfluentialLyketsos, C. G., Lopez, O., Jones, B., Fitzpatrick, A. L., Breitner, J., & DeKosky, S. (2002) · JAMA · doi:10.1001/jama.288.12.1475 · Cited by 2,049 · cited 10×
“Introduction Most patients suffering from dementia experience behavioral and psychological symptoms (BPSD) (Chan et al., 2003; Lyketsos et al., 2002; Lyketsos et al., 2000; Mega et al., 1996; Sink et al., 2004), many of which are particularly disruptive for the patient and her caregivers such as agitation, aggression,…”
BackgroundInfluentialSchneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 1×
“In 2003, the US MedWatch issued a warning about an increased risk of cerebrovascular adverse events with risperidone (US Food and Drug Administration, 2003) and further articles reporting the higher risk of death were published in 2005 (Gill et al., 2005; Schneider et al., 2005).”
BackgroundEffectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206 · cited 3×
“In particular, some important events occurred after the 1st warning: the release of new information about SGA effectiveness in 2006 (Schneider et al., 2006), the approval of risperidone for BPSD in July 2008, the publication of the “dementia antipsychotic withdrawal trial” in January 2009 (Ballard et al.”
BackgroundLyketsos, C. G., Steinberg, M., Tschanz, J. T., Norton, M. C., Steffens, D. C., & Breitner, J. C. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.708 · Cited by 1,144
Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications
Wang, P. S., Schneeweiss, S., Avorn, J., Fischer, M. A., Mogun, H., Solomon, D. H., & Brookhart, M. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052827 · Cited by 959
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
Sink, K. M., Holden, K. F., & Yaffe, K. (2005) · JAMA · doi:10.1001/jama.293.5.596 · Cited by 910
Patient and Caregiver Characteristics and Nursing Home Placement in Patients With Dementia
Yaffe, K. (2002) · JAMA · doi:10.1001/jama.287.16.2090 · Cited by 903 · cited 2×
“, 2003), institutionalization (Steele et al., 1990; Stern et al., 1997; Yaffe et al., 2002), and caregiver distress and depression (Black and Almeida, 2004; Kaufer et al.”
BackgroundPsychiatric symptoms and nursing home placement of patients with Alzheimer's disease
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.8.1049 · Cited by 744
Cited by
French health insurance databases: What interest for medical research?
Moulis, G., Lapeyre-Mestre, M., Palmaro, A., Pugnet, G., Montastruc, J.-L., & Sailler, L. (2015) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2014.11.009 · Cited by 363
Self-citationInternational trends in antipsychotic use: A study in 16 countries, 2005–2014
Hálfdánarson, Ó., Zoëga, H., Aagaard, L., Bernardo, M., Brandt, L., Fusté, A. C., Furu, K., Garuoliené, K., Hoffmann, F., Huybrechts, K. F., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.07.001 · Cited by 282
Ballard, C., Orrell, M., YongZhong, S., Moniz-Cook, E., Stafford, J., Whittaker, R., Woods, B., Corbett, A., Garrod, L., Khan, Z., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15010130 · Cited by 142
Antipsychotic Use in Dementia: Is There a Problem and Are There Solutions?
Kirkham, J., Sherman, C., Velkers, C., Maxwell, C., Gill, S., Rochon, P., & Seitz, D. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716673321 · Cited by 113
“In studies that have evaluated outcomes potentially related to lower antipsychotic use, other psychotropic medication or restraint use has generally not increased,(72,74,79,80) although a few have documented small increases in the use of antidepressants.(76,81,82) This is in keeping with several large-scale studies in…”
ResultPsychotropic drug prescriptions in western European nursing homes
Janus, S. I. M., van Manen, J. G., IJzerman, M. J., & Zuidema, S. U. (2016) · International Psychogeriatrics · doi:10.1017/s1041610216001150 · Cited by 110
Metadata
- Authors
- Gallini, A., Andrieu, S., Donohue, J. M., Oumouhou, N., Lapeyre-Mestre, M., & Gardette, V.
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 24
- Issue
- 1
- Pages
- 95-104
- ISSN
- 0924-977X (ISSN-L)
- OpenAlex
- W2064561288
- Cited by
- 94
- References
- 16
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warnings. https://app.cochat.ai/papers/10.1016/j.euroneuro.2013.09.003
- The paper
- Gallini, A., Andrieu, S., Donohue, J. M., Oumouhou, N., Lapeyre-Mestre, M., & Gardette, V. (2014). Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warnings. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2013.09.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.